Overview

The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery

Status:
Active, not recruiting

Trial end date:
2020-08-01

Target enrollment:

Participant gender:

Summary

In the POPular CABG study we investigate if the addition of ticagrelor, a drug that inhibits blood platelets from clotting, to treatment with aspirin will reduce the rate of saphenous vein graft occlusion as assessed with coronary computed tomography angiography at 1 year after coronary artery bypass grafting surgery.

Phase:

Phase 3

Details

Lead Sponsor:

J.M. ten Berg

Collaborator:

AstraZeneca

Treatments:

Ticagrelor